SubsidieMeestersPrecision Hearing Diagnostics and Augmented-hearing Technologies
The project aims to develop a portable diagnostic device for cochlear synaptopathy and augmented-hearing technologies, transitioning innovative research into practical clinical applications.
Projectdetails
Introduction
Cochlear synaptopathy (CS) is a recently discovered type of sensorineural hearing loss (SNHL) that compromises the integrity of the auditory-nerve population after ageing, noise exposure, or ototoxicity. This SNHL type occurs before the gold-standard clinical audiogram detects hearing problems and has functional consequences for neural sound encoding and communication in noisy environments.
Current Challenges
Despite its presumed high prevalence, CS is neither diagnosed nor treated in clinical practice. There is a WHO-identified need for early diagnosis and treatment of SNHL to reduce the societal and economic burden of hearing loss, and CS diagnosis falls within this category.
Project Overview
In our ERC StG and PoC projects, we developed a robust, encephalogram-based diagnostic test to quantify CS in humans. Based on this test, we individualize hearing-impaired auditory models to design hearing-aid signal processing that compensates for CS. Our model-based, augmented-hearing algorithms can offer an accessible treatment to those suffering from CS and are based on a clever and versatile neural-network architecture that enables real-time sound processing.
Implementation Plan
In this project, we plan to implement our diagnostic CS test (TRL4) in a portable medical device and perform clinical trials with early adopters and first-point-of-contact centers to demonstrate its patient benefit and application range in a real-world clinical context (TRL5-6).
Hardware Development
Secondly, we aim to develop hardware demonstrators that embed our augmented-hearing sound processors. These real-time FPGA processors (TRL5) will be tailored for market entry in the hearable, hearing-aid, and cochlear-implant sectors.
Business Strategy
Along with consolidating our IP portfolio and setting out a business strategy, this challenge on Medical Technology and Devices will enable us to transition our proof-of-concept research discoveries to market with this project: EarDiTech: Precision Hearing Diagnostics and Augmented-hearing Technologies.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.416 |
| Totale projectbegroting | € 2.499.416 |
Tijdlijn
| Startdatum | 1-8-2022 |
| Einddatum | 31-7-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- UNIVERSITEIT GENTpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationSThe NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring. | EIC Transition | € 2.497.750 | 2022 | Details |
Predictive REagent-Antibody Replacement Technology stage 2-TranslationPRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment. | EIC Transition | € 800.000 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Predictive REagent-Antibody Replacement Technology stage 2-Translation
PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Rehabilitation and Diagnosis of Hearing Loss based on Electric Acoustic InteractionThe READIHEAR project aims to develop innovative diagnostics and a novel auditory prosthetic to enhance hearing restoration through electric-acoustic stimulation for all ages with hearing loss. | ERC COG | € 1.978.875 | 2022 | Details |
Solving the dynamic range problem of hearing: deciphering and harnessing cochlear mechanisms of sound intensity codingDynaHear aims to elucidate the relationship between synaptic heterogeneity and functional diversity in spiral ganglion neurons to advance understanding of sound intensity coding and improve hearing therapies. | ERC ADG | € 2.499.411 | 2023 | Details |
Soft optoelectronics and ion-based circuits for diagnostics and closed-loop neuromodulation of the auditory pathwayDevelop a fully implantable, biocompatible electro-optical neurostimulation system using ion gated transistors and OLEDs to enhance neural signal acquisition and treatment of sensory dysfunctions. | ERC STG | € 1.499.213 | 2023 | Details |
Distributed wireless EEG sensor patches for auditory attention decoding in hearing technologyDevelop a discreet, wireless EEG system using modular patches to enhance hearing aids by decoding auditory attention, improving communication for hearing-impaired individuals. | ERC POC | € 150.000 | 2024 | Details |
Rehabilitation and Diagnosis of Hearing Loss based on Electric Acoustic Interaction
The READIHEAR project aims to develop innovative diagnostics and a novel auditory prosthetic to enhance hearing restoration through electric-acoustic stimulation for all ages with hearing loss.
Solving the dynamic range problem of hearing: deciphering and harnessing cochlear mechanisms of sound intensity coding
DynaHear aims to elucidate the relationship between synaptic heterogeneity and functional diversity in spiral ganglion neurons to advance understanding of sound intensity coding and improve hearing therapies.
Soft optoelectronics and ion-based circuits for diagnostics and closed-loop neuromodulation of the auditory pathway
Develop a fully implantable, biocompatible electro-optical neurostimulation system using ion gated transistors and OLEDs to enhance neural signal acquisition and treatment of sensory dysfunctions.
Distributed wireless EEG sensor patches for auditory attention decoding in hearing technology
Develop a discreet, wireless EEG system using modular patches to enhance hearing aids by decoding auditory attention, improving communication for hearing-impaired individuals.